CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells.
about
Clinical and laboratory prognostic indicators in chronic lymphocytic leukemiaThe pathogenesis of chronic lymphocytic leukemiaCD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cellsGene expression signatures of radiation response are specific, durable and accurate in mice and humans.Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemiaDistinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemiaMicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of originLarge-scale analysis of DNA methylation in chronic lymphocytic leukemiaDifferential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells.Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia.In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia.The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia.Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocationProgrammed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemiaDipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemiaThe genomic landscape of chronic lymphocytic leukemia: clinical implications.Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia.The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells.Higher gene expression variability in the more aggressive subtype of chronic lymphocytic leukemia.A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL.CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivoState-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera.Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivoT-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients.Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agentsPerifosine as a potential novel anti-telomerase therapy.Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments.CD38 and chronic lymphocytic leukemia: a decade later.Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.Chronic lymphocytic leukemia/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression.Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia.c-Cbl tyrosine kinase-binding domain mutant G306E abolishes the interaction of c-Cbl with CD38 and fails to promote retinoic acid-induced cell differentiation and G0 arrest
P2860
Q26830323-3AC2351E-5FCF-4893-8312-63979E396A28Q27025715-694639C1-B7EB-4B0C-8812-9154F85DF7A3Q30484805-A32CF2D1-5C78-4C4E-9E9D-F565F24C6B5DQ33326641-6E9F448F-0930-4969-B5BD-E842455F62D7Q33350258-529DCF94-E322-4414-B871-1F0EA815640DQ33409459-57630446-B6C9-4AD6-A24D-0022F98FE438Q33655756-DDBE72D4-067A-48B2-97F7-72EB78475CC9Q33804706-1C9AB71E-DB02-4ACA-8B5A-83818FD91CC7Q33847322-B6F3D6A9-8F59-4810-A120-F7E2DF074506Q33849548-4A4876AD-D6C6-4980-AB38-3652C05E41CAQ33859881-9BE0B13B-80BF-439C-924B-8D2E471C8661Q34005556-7171DACF-73A2-44F6-9119-32C4E6365D36Q34012864-E4FA2F7E-A439-4F7C-AD73-619947414F46Q34078726-E9EFC572-CECD-4D05-A592-8CCB1D325904Q34097631-D63982C0-D88E-4238-9D65-7A9AAC1937F1Q34166551-CE79515C-10FE-461E-B592-6512E4A6030BQ34245048-2A40AD18-0917-4A50-BE4D-15690D409575Q34349298-497DA7E9-2299-421A-9F54-CFB838F8C502Q34710882-AE68F0F1-A7AF-4C01-8F82-6A9D09F836DFQ34925487-71FD1A5A-EC2E-4F43-9221-D1A95C1E1AE5Q35011166-802CD07C-E265-47EE-B34E-9D76E87A618BQ35021249-4C59000E-CF5D-49AC-8117-2CD59D82D96CQ35029969-FA6E1069-6F30-4F98-91D2-CAE860B1DEAAQ35188629-DA225DC9-C797-48E5-B2E3-392B0CF5FCEFQ35717883-8F48B101-1041-4FA2-9AD6-5051377BDB81Q35781372-C8200A5E-8EED-4D47-AB0E-8D5A805752FEQ35860550-0EBD5099-B2F7-4424-A5C2-BCFD76083645Q35861964-C0A590BA-AB5F-469C-A27C-70D631CB412DQ35876861-356877E4-E3BA-4421-9FAA-57609D22B62FQ36016378-58D53BB1-77E8-4386-8717-7FE3ACDE8AE8Q36072490-15C51F90-9817-40AC-8463-B0DCE1555A21Q36250927-15F26D47-DD8F-496F-9454-434743A9BBACQ36293814-98014868-FDA5-4E7A-8BE8-B5F41652B7B7Q36355806-32843E2B-5537-4B3A-AB9B-599C38E6F7BDQ36520447-41902993-F317-415D-8CC9-6AD1F77230B9Q36615126-74861A3C-E235-48E7-848B-599B6F074442Q36862781-575926A5-6CF6-4EB5-ACE8-50ECCEBE68C5Q36979738-75A4DDCD-7255-4128-BA89-0C59BF5804DDQ37268297-CCF9F108-7A04-40A1-95FA-B2E545E45A5FQ37377645-CA3AFB8B-3F7D-4723-8570-E13BD65FC27B
P2860
CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
CD38 expression labels an acti ...... ched in proliferating B cells.
@ast
CD38 expression labels an acti ...... ched in proliferating B cells.
@en
type
label
CD38 expression labels an acti ...... ched in proliferating B cells.
@ast
CD38 expression labels an acti ...... ched in proliferating B cells.
@en
prefLabel
CD38 expression labels an acti ...... ched in proliferating B cells.
@ast
CD38 expression labels an acti ...... ched in proliferating B cells.
@en
P2093
P2860
P1433
P1476
CD38 expression labels an acti ...... ched in proliferating B cells.
@en
P2093
Carlo Calissano
Cristina Sison
Kanti R Rai
Nicholas Chiorazzi
Rajendra N Damle
Sonal Temburni
Sophia Yancopoulos
Steven L Allen
Taraneh Banapour
P2860
P304
P356
10.1182/BLOOD-2007-04-083832
P407
P577
2007-08-07T00:00:00Z